| 期刊簡介 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | EClinicalMedicine LetPub Score 9.1
50 ratings
Rate
Reputation 9.5 Influence 8.6 Speed 9.7 | ||||||||||||||||
| 期刊簡稱 | |||||||||||||||||
| ISSN | 2589-5370 | ||||||||||||||||
| h-index | N.A. | ||||||||||||||||
| CiteScore |
| ||||||||||||||||
| 自引率 (2023-2024) | 0.00%自引率趨勢 | ||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||
| 官方網站 | https://www.thelancet.com/journals/eclinm/home | ||||||||||||||||
| 在線稿件提交 | |||||||||||||||||
| 開放訪問 | Yes | ||||||||||||||||
| 出版商 | Elsevier | ||||||||||||||||
| 主題領域 | Medicine | ||||||||||||||||
| 出版國/地區 | United Kingdom | ||||||||||||||||
| 發行頻率 | |||||||||||||||||
| 創刊年 | 0 | ||||||||||||||||
| 每年文章數 | 511每年文章數趨勢 | ||||||||||||||||
| 黃金OA百分比 | 78.40% | ||||||||||||||||
OA Related Info | APC: Yes（ USD5000; ） APC waiver：Check Notes Other charges: No Keywords: health systems、healthcare、clinical medicine Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q1
| ||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2589-5370%5BISSN%5D | ||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 10 Weeks | ||||||||||||||||
| 競爭力 * | 來自作者的數據: | ||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [EClinicalMedicine] 的評論 | 撰寫評論 |
| 作者: mlllll 領域: 医学 審稿時間: 1.0 month(s) 結果: 拒稿 撰寫評論 |
2024-10-31 09:37:46 評論於 2024.10.22 Submitted 2024.10.29 Rejected  (0) 讚！ | mlllll  |
| 作者: petshi530 領域: 医学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2022-11-22 17:04:09 評論於 The Lancet series has a high impact factor as soon as it is released, which is great. The publication fee is high, and it focuses on clinical research. It is worth considering for high-level multi-center studies. There is also a chance for high-level single-center large cohorts or randomized controlled trials. The review process is quite strict, so it needs to be taken seriously. (1) 讚！ | petshi530 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
